We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Bioanalysis
BioTechniques
Future Drug Discovery
Future Medicinal Chemistry
Future Science OA
International Journal of Pharmacokinetics
Pharmaceutical Patent Analyst
Therapeutic Delivery
Review

Transdermal delivery of biopharmaceuticals: dream or reality?

    Sahitya Katikaneni

    *Author for correspondence:

    E-mail Address: sahityakatikaneni@gmail.com

    Corium International, Menlo Park, CA, USA

    Search for more papers by this author

    Published Online:30 Sep 2015https://doi.org/10.4155/tde.15.60

    Abstract

    The skin being the largest organ of the body presents a potential route for administration of drugs. Passive transdermal products such as gels, creams and patches deliver drugs effectively across the skin. However, this approach is limited to lipophilic molecules with low molecular weights. Passive transdermal delivery of proteins and peptides which are hydrophilic with high molecular weights is negligible. This led to the development of various ways of surmounting the skin barrier so as to make this route feasible for peptide and protein delivery. The current article reviews various active transdermal technologies with special emphasis on microneedle mediated delivery. Microneedles, especially dissolvable microneedles present an excellent platform for protein and peptide delivery. Significant advances have been made in the past decade in this area. Published literature shows a broad spectrum of molecules being delivered successfully via microneedles. However, success in clinic will give a boost to all the efforts and advances made in this field so far.

    References

    • 1 BioPharma. FDA Biopharmaceutical Product Approvals and Trends in 2012. www.biopharma.com/FDA_2012_approvals_article.pdf.Google Scholar
    • 2 United States Department of Labor, Occupational Safety and Health Administration. Healthcare Wide Hazards: Needlestick/Sharps Injuries. www.osha.gov/SLTC/etools/hospital/hazards/sharps/sharps.html.Google Scholar
    • 3 Wu Y, Gao Y, Qin G et al. Sustained release of insulin through skin by intradermal microdelivery system. Biomed. Microdevices 12(4), 665–671 (2010).Crossref, Medline, CAS, Google Scholar
    • 4 Kalluriv H, Banga AK. Transdermal delivery of proteins. AAPS PharmSciTech 12(1), 431–441 (2011).Crossref, Medline, Google Scholar
    • 5 Dhote V, Bhatnagar P, Mishra PK, Mahajan SC, Mishra DK. Iontophoresis: a potential emergence of a transdermal drug delivery system. Sci. Pharm. 80(1), 1–28 (2011).Crossref, Medline, Google Scholar
    • 6 Semalty A, Semalty M, Singh R, Saraf SK, Saraf S. Iontophoretic drug delivery system: a review. Technol. Health Care 15(4), 237–245 (2007).Crossref, Medline, Google Scholar
    • 7 Polat BE, Hart D, Langer R, Blankschtein D. Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends. J. Control. Release 152(3), 330–348 (2011).Crossref, Medline, CAS, Google Scholar
    • 8 Polat BE, Blankschtein D, Langer R. Low-frequency sonophoresis: application to the transdermal delivery of macromolecules and hydrophilic drugs. Expert Opin. Drug Deliv. 7(12), 1415–1432 (2010).Crossref, Medline, CAS, Google Scholar
    • 9 Escobar-Chavez JJ, Bonilla-Martinez D, Villegas-Gonzalez MA, Molina-Trinidad E, Casas-Alancaster N, Revilla-Vazquez AL. Microneedles: a valuable physical enhancer to increase transdermal drug delivery. J. Clin. Pharmacol. 51(7), 964–977.Crossref, Medline, Google Scholar
    • 10 Dubin CH. Transdermal, topical and subcutaneous drug delivery: extending pipelines and improving self-administration. Drug Devel. Deliv. 13, 44–52 (2013).Google Scholar
    • 11 Ito Y, Murano H, Hamasaki N, Fukushima K, Takada K. Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. Int. J. Pharm. 407(1–2), 126–131 (2011).Crossref, Medline, CAS, Google Scholar
    • 12 Daddona PE, Matriano JA, Mandema J, Maa YF. Parathyroid hormone (1–34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm. Res. 28(1), 159–165 (2011).Crossref, Medline, CAS, Google Scholar
    • 13 Ameri M, Daddona PE, Maa YF. Demonstrated solid-state stability of parathyroid hormone PTH(1–34) coated on a novel transdermal microprojection delivery system. Pharm. Res. 26(11), 2454–2463 (2009).Crossref, Medline, CAS, Google Scholar
    • 14 McVey E, Hirsch L, Sutter DE et al. Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion. J. Diabetes Sci. Technol. 6(4), 743–754 (2012).Crossref, Medline, Google Scholar
    • 15 Ito Y, Nakahigashi T, Yoshimoto N, Ueda Y, Hamasaki N, Takada K. Transdermal insulin application system with dissolving microneedles. Diabetes Technol. Ther. 14(10), 891–899 (2012).Crossref, Medline, CAS, Google Scholar
    • 16 Martanto W, Davis SP, Holiday NR, Wang J, Gill HS, Prausnitz MR. Transdermal delivery of insulin using microneedles in vivo. Pharm. Res. 21(6), 947–952 (2004).Crossref, Medline, CAS, Google Scholar
    • 17 Qiu Y, Qin G, Zhang S, Wu Y, Xu B, Gao Y. Novel lyophilized hydrogel patches for convenient and effective administration of microneedle-mediated insulin delivery. Int. J. Pharm. 437(1–2), 51–56 (2012).Crossref, Medline, CAS, Google Scholar
    • 18 Lee JW, Park JH, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. Biomaterials 29(13), 2113–2124 (2008).Crossref, Medline, CAS, Google Scholar
    • 19 Burton SA, Ng CY, Simmers R et al. Rapid intradermal delivery of liquid formulations using a hollow microstructured array. Pharm. Res. 28(1), 31–40 (2011).Crossref, Medline, CAS, Google Scholar
    • 20 Lee JW, Choi SO, Felner EI, Prausnitz MR. Dissolving microneedle patch for transdermal delivery of human growth hormone. Small 7(4), 531–539 (2011).Crossref, Medline, CAS, Google Scholar
    • 21 Fukushima K, Ise A, Morita H et al. Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. Pharm. Res. 28(1), 7–21 (2010).Crossref, Medline, Google Scholar
    • 22 Park JH, Allen MG, Prausnitz MR. Polymer microneedles for controlled-release drug delivery. Pharm. Res. 23(5), 1008–1019 (2006).Crossref, Medline, CAS, Google Scholar
    • 23 Li G, Badkar A, Kalluri H, Banga AK. Microchannels created by sugar and metal microneedles: characterization by microscopy, macromolecular flux and other techniques. J. Pharm. Sci. 99(4), 1931–1941 (2010).Crossref, Medline, CAS, Google Scholar
    • 24 3M. Microneedle Drug Delivery Systems. http://solutions.3m.com/wps/portal/3M/en_WW/3M-DDSD/Drug-Delivery-Systems/transdermal/microneedle/.Google Scholar
    • 25 Kalluri H, Banga AK. Formation and closure of microchannels in skin following microporation. Pharm. Res. 28(1), 82–94 (2011).Crossref, Medline, CAS, Google Scholar
    • 26 Bal S, Kruithof AC, Liebl H et al. In vivo visualization of microneedle conduits in human skin using laser scanning microscopy. Laser Phys. Lett. 7(3), 242–246 (2010).Crossref, Google Scholar
    • 27 Brogden NK, Milewski M, Ghosh P, Hardi L, Crofford LJ, Stinchcomb AL. Diclofenac delays micropore closure following microneedle treatment in human subjects. J. Control. Release. 163(2), 220–229 (2012).Crossref, Medline, CAS, Google Scholar
    • 28 van der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for (trans)dermal drug and vaccine delivery. J. Control. Release 161(2), 645–655 (2012).Crossref, Medline, CAS, Google Scholar
    • 29 Nava-Arzaluz MG, Calderon-Lojero I, Quintanar-Guerrero D, Villalobos-Garcia R, Ganem-Quintanar A. Microneedles as transdermal delivery systems: combination with other enhancing strategies. Curr. Drug Deliv. 9(1), 57–73 (2012).Crossref, Medline, CAS, Google Scholar